Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Pricing Reform In US: It’s Over For 2017

Executive Summary

There's lots of buzz about drug pricing actions, be they executive or legislative. But the die is cast for this year: real reforms will have to wait.


Related Content

Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood
340B Program Controls: House Committee Launches Investigation
Can US FDA Save Pharma From Price Controls?
Breakthrough-Style Program For ANDAs Added To House User Fee Bill
Generic Priority Review Expanded In Senate User Fee Bill
Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts